Aytu BioPharma, Inc. (AYTU)
Largest Insider Buys in Sector
AYTU Stock Price History Chart
AYTU Stock Performance
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine …
Insider Activity of Aytu BioPharma, Inc.
Over the last 12 months, insiders at Aytu BioPharma, Inc. have bought $0 and sold $0 worth of Aytu BioPharma, Inc. stock.
On average, over the past 5 years, insiders at Aytu BioPharma, Inc. have bought $2.76M and sold $40.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $22,428 was made by PYSZCZYMUKA GREG (Chief Commerical Officer) on 2023‑06‑16.
List of Insider Buy and Sell Transactions, Aytu BioPharma, Inc.
| 2023-06-16 | Chief Commerical Officer | 12,000 0.3307% | $1.87 | $22,428 | +53.30% | |||
| 2023-06-14 | Chief Executive Officer | 14,000 0.3999% | $1.86 | $26,079 | +58.66% | |||
| 2022-12-19 | Chief Executive Officer | 112,371 0.1842% | $0.22 | $25,048 | -47.51% | |||
| 2022-12-19 | Chief Commercial Officer | 100,000 0.18% | $0.24 | $24,480 | -47.51% | |||
| 2022-11-18 | Chief Executive Officer | 222,000 0.3705% | $0.24 | $52,614 | -49.58% | |||
| 2022-11-18 | Chief Financial Officer | 90,000 0.1458% | $0.23 | $20,700 | -49.58% | |||
| 2020-12-11 | director | 1.33M 9.5911% | $6.00 | $8M | -17.04% | |||
| 2020-04-27 | Sale | director | 5.11M 4.0608% | $1.82 | $9.3M | -49.75% | ||
| 2020-04-15 | Sale | 10 percent owner | 92,777 0.082% | $1.55 | $144,092 | -33.23% | ||
| 2020-03-10 | Sale | director | 22.03M 43.1464% | $1.42 | $31.2M | -41.46% | ||
| 2019-12-20 | 26,000 0.1525% | $0.88 | $22,880 | +39.53% | ||||
| 2019-12-19 | 52,788 0.3082% | $0.85 | $44,870 | +44.58% | ||||
| 2019-12-19 | 55,000 0.3354% | $0.89 | $48,824 | +44.58% | ||||
| 2018-12-21 | Sale | Chief Financial Officer | 3,330 0.053% | $0.81 | $2,711 | +74.68% | ||
| 2018-03-06 | Chief Executive Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | |||
| 2018-03-06 | Chief Operating Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | |||
| 2018-03-06 | Chief Financial Officer | 66,600 0.6021% | $0.45 | $29,970 | -49.76% | |||
| 2016-11-02 | Chief Executive Officer | 333,332 4.4318% | $1.68 | $559,998 | -80.47% | |||
| 2016-11-02 | Chief Operating Officer | 333,332 4.4318% | $1.68 | $559,998 | -80.47% | |||
| 2016-11-02 | Chief Financial Officer | 133,332 1.7727% | $1.68 | $223,998 | -80.47% |
Insider Historical Profitability
| DOCKERY CARL | director | 5047591 82.0881% | $1.84 | 1 | 0 | |
| ARMISTICE CAPITAL, LLC | director | 1333334 21.6838% | $1.84 | 3 | 2 | +22.36% |
| Disbrow Jarrett | Chief Operating Officer | 439490 7.1474% | $1.84 | 4 | 0 | |
| Gould Gregory A | Chief Financial Officer | 273565 4.4489% | $1.84 | 1 | 0 | |
| Green David A | Chief Financial Officer | 266250 4.33% | $1.84 | 1 | 1 |
Institutional Investor Ownership
| Nantahala Capital Management Llc | $3.3M | 18.2 | 1.09M | 0% | +$0 | 0.15 | |
| Stonepine Capital Management Llc | $1.44M | 7.91 | 472,469 | 0% | +$0 | 0.09 | |
| Renaissance Technologies | $217,000.00 | 1.19 | 71,323 | +3.48% | +$7,301.99 | <0.0001 | |
| Geode Capital Management | $105,109.00 | 0.58 | 34,563 | +4.59% | +$4,613.32 | <0.0001 | |
| The Vanguard Group | $84,780.00 | 0.47 | 27,888 | +2.34% | +$1,936.49 | <0.0001 |